1. Market Research
  2. > Pharmaceutical
  3. > Prescription Drug Market Trends
Company Profile: Bayer

Company Profile: Bayer

  • December 2017
  • 48 pages
  • ID: 5336385
  • Format: PDF
  • Datamonitor Healthcare


Table of Contents

Updated analysis and forecasts based on Q3 2017 company-reported sales.

PharmaVitae explores Bayer’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016–26.

Overview – Bayer’s prescription drug sales will experience modest growth up to 2026.
Out to 2022 – Bayer’s prescription drug sales will grow rapidly out to 2022, reaching total sales of $22.8bn.
Out to 2026 – Following major patent expiries in 2023, sales will marginally decline to $22.5bn in 2026.
Pipeline – Diabetic nephropathy treatment finerenone set for approval in 2020.
Events – Completion of Monsanto acquisition, and updates to Xarelto’s label.

Bayer’s prescription drug sales will experience modest growth up to 2026.
Genitourinary remains a key therapy area, despite little RandD involvement. Sales of contraceptive franchises Yaz and Mirena will drive sales in the segment.
Internal cardiovascular research will provide long-term sales growth.
Bayer’s in-licensing strategy will continue to have moderate success.

Model updates
Added vilaprisan
ODM-201 changed to darolutamide
Copanlisib changed to Aliqopa.

Analysis structure
Explore and visualize revenue dynamics in Bayer’s portfolio out to 2026 using 10-year in-house sales forecasts segmented by the following sections.

Company context
How is Bayer strategically poised out to 2026?
What are Bayer’s key strengths, weaknesses, opportunities, and threats?
What are Bayer’s key catalysts during the current year?

Facts and figures
What is Bayer’s forecasted sales performance out to 2026?
What is the revenue trajectory of Bayer’s current top 10 products out to 2026?
Which therapy areas will experience the largest growth and decline?
What are the portfolio weightings of Bayer based on the lifecycle of its products?

Key therapy areas
Why will specific therapy areas experience the largest growth and decline?
What are the detailed competitive dynamics at play in Bayer’s important therapeutic markets?
How is Bayer adapting strategically to internal and external headwinds?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Anti-obesity Prescription Drugs Market Research Report by Drug Class, by Age Group, by Distribution Channel - Global Forecast to 2025 - Cumulative Impact of COVID-19

  • $ 4949
  • February 2021
  • 184 pages

Anti-obesity Prescription Drugs Market Research Report by Drug Class (Bupropion and Naltrexone, Liraglutide, Lorcaserin, Orlistat, and Phentermine and Topiramate), by Age Group (Adult and Pediatric), by ...

  • World
  • Prescription Drug
  • Industry analysis

Global ePharmacies Industry $ 5450 April 2021

Company Analysis: Takeda $ 3000 January 2021

Company Analysis: Shionogi $ 3000 January 2021


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on